4-ethyl-1,3-dihydro-5-[4-(1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one | 101183-99-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-ethyl-1,3-dihydro-5-[4-(1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one
• 英文别名: 4-Ethyl-5-(4-imidazol-1-ylbenzoyl)-1,3-dihydroimidazol-2-one
• CAS: 101183-99-7
• 化学式: C₁₅H₁₄N₄O₂
• 分子量: 282.302
• InChiKey: FIYSLYBKJKWZMC-UHFFFAOYSA-N

物化性质

• 熔点：
  313-315 °C (decomp)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  咪唑 、 4-Ethyl-5-(4-fluorobenzoyl)-1,3-dihydroimidazol-2-one 反应 40.0h， 以89%的产率得到4-ethyl-1,3-dihydro-5-[4-(1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one
  参考文献：
  名称：

  Cardiotonic agents. 2. (Imidazolyl)aroylimidazolones, highly potent and selective positive inotropic agents

  摘要：

  A series of 4-alkyl-1,3-dihydro-5-[(1H-imidazolyl)benzoyl]-2H-imidazol-2-ones 9 was synthesized and evaluated in vitro for positive inotropic and cyclic AMP phosphodiesterase inhibitory activity. A wide range of inotropic and enzyme-inhibitory potencies was observed, substitution on the imidazolyl moiety being the major determinant of activity. The 4-ethyl-5-[4-(1H-imidazol-1-yl)benzoyl] congener 9g exhibited the highest potency in vitro. Incorporation of a methyl group at the imidazolyl 2-position gave 9h, which was less potent but remarkably selective in vivo for positive inotropic effects over heart rate and hypotensive effects.

  DOI：

  10.1021/jm00391a013

文献信息

• Process for the preparation of imidazolonecarbonylarylimidazoles
  申请人：Schering A.G.

  公开号：US04709043A1

  公开（公告）日：1987-11-24

  Novel imidazolonecarbonylarylimidazoles are described having cardiovascular properties, especially as cardiotonic agents in the treatment of congestive heart failure. Pharmaceutical formulations containing such compounds are also provided. Further, a novel process for the preparation of the compounds and intermediates useful thereto of this invention is disclosed.

  本发明描述了具有心血管特性的新型咪唑烷酰基芳基咪唑，特别是作为治疗充血性心力衰竭的心脏强效药物。此外，还提供了含有这种化合物的制药配方。此外，还揭示了一种制备该化合物和中间体的新方法。
• Cardiotonic 1,3-dihydro-4-[[(imidazol-1-yl)aryl]carbonyl]imidazol-2-ones
  申请人：Schering A.G.

  公开号：US04556665A1

  公开（公告）日：1985-12-03

  Novel imidazolonecarbonylarylimidazoles of the formula: ##STR1## are described having cardiovascular properties, especially as cardiotonic agents in the treatment of congestive heart failure. Pharmaceutical formulations containing such compounds are also provided. Further, a novel process for the preparation of the compounds and intermediates useful thereto of this invention is disclosed.

  本文描述了一种式为##STR1##的新型咪唑酮酰基芳基咪唑衍生物，具有心血管特性，特别是作为心力衰竭治疗中的强心剂。本文还提供了含有这种化合物的制药配方。此外，本发明还揭示了一种制备这种化合物及其有用中间体的新方法。
• Prodrug derivatives of the cardiotonic agent 4-ethyl-1,3-dihydro-5-[4-(2-methyl-1H-imidazol-1-yl)-benzoyl]]-2H-imidazol-one
  申请人：BERLEX LABORATORIES, INC.

  公开号：EP0264729A2

  公开（公告）日：1988-04-27

  Orally active prodrug derivatives of the cardiotonic agent 4-ethyl-1,3-dihydro-5-[4-(2-methyl-1H-imidazol-1-yl)­benzoyl]-2H-imidazol-2-one are disclosed. Pharmaceutical formulations containing such compounds are also provided.

  本研究公开了强心剂 4-乙基-1,3-二氢-5-[4-(2-甲基-1H-咪唑-1-基)苯甲酰基]-2H-咪唑-2-酮的口服活性原药衍生物。还提供了含有此类化合物的药物制剂。
• HAGEDORN, A. A., III;ERHARDT, P. W.;LUMMA, W. C., JR.;WOHL, R. A.;CARTOR,+, J. MED. CHEM., 30,(1987) N 8, 1342-1347
  作者：HAGEDORN, A. A., III、ERHARDT, P. W.、LUMMA, W. C., JR.、WOHL, R. A.、CARTOR,+

  DOI：——

  日期：——
• Imidazolonecarbonylarylimidazoles; method of manufacture, method of use and compositions useful thereof
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：EP0169164B1

  公开（公告）日：1990-01-31